| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Kristine Peterson is Director at MLYS, with reported holdings spanning 3 companies. Kristine Peterson's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $201K at current prices.
Kristine Peterson's largest disclosed position is in MLYS as Director, worth about $198K.
Kristine Peterson has 31 Form 4 filings on record from July 2015 to October 2026, across 6 companies: Director at Mineralys Therapeutics (MLYS), 2026; Director at ArriVent BioPharma (AVBP), 2024–2026; Director at Immunocore (IMCR), 2024–2026, and 3 more.
The 48 reported transactions were 42 option or other derivative awards, 4 option exercises, 1 stock award and 1 open-market sale.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $3.3M.
The only open-market sale was 163,500 shares of AMRN at an average $20.02 on February 22, 2019, about $3.3M.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 22, 2019 | AMRN Amarin Corp Plc\uk | Director | Sale+OE | 163,500 | $20.02 | $3,274,038.45 | - |